Last reviewed · How we verify
MesoPher
At a glance
| Generic name | MesoPher |
|---|---|
| Sponsor | Joachim Aerts, MD PhD |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- dENdritic Cell Therapy Combined With SURgEry in Mesothelioma (PHASE1)
- DENdritic Cell Immunotherapy for Mesothelioma (PHASE2, PHASE3)
- MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MesoPher CI brief — competitive landscape report
- MesoPher updates RSS · CI watch RSS
- Joachim Aerts, MD PhD portfolio CI